Pharmacological Targets of Kaempferol Within Inflammatory Pathways-A Hint Towards the Central Role of Tryptophan Metabolism.

antioxidant indoleamine 2,3-dioxygenase kaempferol neopterin phytochemical tryptophan

Journal

Antioxidants (Basel, Switzerland)
ISSN: 2076-3921
Titre abrégé: Antioxidants (Basel)
Pays: Switzerland
ID NLM: 101668981

Informations de publication

Date de publication:
21 Feb 2020
Historique:
received: 27 01 2020
revised: 16 02 2020
accepted: 18 02 2020
entrez: 27 2 2020
pubmed: 27 2 2020
medline: 27 2 2020
Statut: epublish

Résumé

The flavonoid kaempferol is almost ubiquitously contained in edible and medicinal plants and exerts a broad range of interesting pharmacological activities. Interactions with central inflammatory processes can be exploited to treat or attenuate symptoms of disorders associated with chronic immune activation during infections, malignancies, and neurodegenerative or cardiovascular disorders. Many drugs, phytochemicals, and nutritional components target the catabolism of the essential amino acid tryptophan by indoleamine 2,3-dioxygenase 1 (IDO-1) for immunomodulation. We studied the effects of kaempferol by in vitro models with human peripheral blood mononuclear cells (PBMC) and THP-1 derived human myelomonocytic cell lines. Kaempferol suppressed interferon-γ dependent immunometabolic pathways: Formation of the oxidative stress biomarker neopterin and catabolism of tryptophan were inhibited dose-dependently in stimulated cells. In-silico docking studies revealed a potential interaction of kaempferol with the catalytic domain of IDO-1. Kaempferol stimulated nuclear factor kappa B (NF-κB) signaling in lipopolysaccharide (LPS)-treated THP-1 cells, thereby increasing the mRNA expression of interleukin (IL) 1 beta, tumor necrosis factor, and nuclear factor kappa B subunit 1, while IL6 was downregulated. Data suggest that concerted effects of kaempferol on multiple immunologically relevant targets are responsible for its immunomodulatory activity. However, the immunosuppressive effects may be more relevant in a T-cell dominated context.

Identifiants

pubmed: 32098277
pii: antiox9020180
doi: 10.3390/antiox9020180
pmc: PMC7070836
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Austrian Science Fund FWF
ID : P 29671
Pays : Austria
Organisme : Austrian Science Fund
ID : P 29671
Organisme : Austrian Science Fund
ID : T703

Déclaration de conflit d'intérêts

The authors declare no competing financial interests. The founding sponsors had no role in the design of the study; in the collection, analyses, or interpretation of data; in writing of the manuscript, and in the decision to publish the results.

Références

ALTEX. 2018 Nov 27;36(2):231-244
pubmed: 30488083
J Cell Biol. 1988 Mar;106(3):761-71
pubmed: 2450098
FEBS Open Bio. 2013 Sep 07;3:450-2
pubmed: 24251110
Cell Death Differ. 2002 Oct;9(10):1069-77
pubmed: 12232795
FASEB J. 1991 Aug;5(11):2516-22
pubmed: 1907934
J Pharm Biomed Anal. 2018 Feb 5;149:66-69
pubmed: 29101817
Proteins. 2009 Apr;75(1):187-205
pubmed: 18814299
J Med Chem. 2007 Feb 22;50(4):726-41
pubmed: 17300160
Oncogene. 2003 Dec 8;22(56):8961-82
pubmed: 14663476
Biochem J. 1989 Sep 15;262(3):861-6
pubmed: 2511835
BMC Complement Altern Med. 2014 Dec 16;14:503
pubmed: 25515049
Nucleic Acids Res. 2001 May 1;29(9):e45
pubmed: 11328886
Am J Physiol Gastrointest Liver Physiol. 2003 Jun;284(6):G980-8
pubmed: 12736148
Cell Mol Immunol. 2015 Jan;12(1):5-23
pubmed: 25263488
Neurosci Biobehav Rev. 2018 Jul;90:16-25
pubmed: 29608993
Nucleic Acids Res. 2002 May 1;30(9):e36
pubmed: 11972351
Clin Chem. 1997 Dec;43(12):2424-6
pubmed: 9439467
Gastroenterology. 2001 Apr;120(5):1251-62
pubmed: 11266388
J Exp Med. 1984 Jul 1;160(1):310-6
pubmed: 6429267
Oxid Med Cell Longev. 2018 Jan 14;2018:2980295
pubmed: 29576845
Biopharm Drug Dispos. 2009 Oct;30(7):356-65
pubmed: 19722166
Cell. 1989 Sep 8;58(5):923-31
pubmed: 2476237
Xenobiotica. 1998 Apr;28(4):389-401
pubmed: 9604302
Antioxid Redox Signal. 2009 Sep;11(9):2245-63
pubmed: 19361274
Inflamm Res. 2011 Feb;60(2):127-35
pubmed: 20740299
Redox Rep. 2013;18(3):88-94
pubmed: 23601165
Cytokine. 2010 Apr;50(1):1-14
pubmed: 20036577
Toxicol In Vitro. 2001 Feb;15(1):3-6
pubmed: 11259863
FEBS Lett. 2005 Oct 10;579(24):5343-6
pubmed: 16194534
Phytomedicine. 2013 Oct 15;20(13):1190-5
pubmed: 23867649
J Agric Food Chem. 2006 Dec 27;54(26):9798-804
pubmed: 17177504
Nat Immunol. 2011 Jul 19;12(8):695-708
pubmed: 21772278
Am J Clin Nutr. 1998 Jul;68(1):60-5
pubmed: 9665097
J Acquir Immune Defic Syndr (1988). 1990;3(9):873-6
pubmed: 2166783
Adv Enzyme Regul. 1984;22:27-55
pubmed: 6382953
Biol Chem. 2009 Feb;390(2):115-23
pubmed: 19040353
Immunol Lett. 1989 Dec;23(2):103-8
pubmed: 2517264
Molecules. 2019 Jun 19;24(12):
pubmed: 31248102
Biochem Biophys Res Commun. 2010 Sep 3;399(4):642-6
pubmed: 20691158
Mol Biochem Parasitol. 1986 Sep;20(3):215-24
pubmed: 3093859
J Biol Chem. 2019 Aug 30;294(35):12866-12879
pubmed: 31324718
Appl Environ Microbiol. 1989 May;55(5):1203-8
pubmed: 2757380
PLoS One. 2015 May 26;10(5):e0128132
pubmed: 26010916
Clin Chim Acta. 2006 Feb;364(1-2):82-90
pubmed: 16139256
Biomed Res Int. 2018 Nov 12;2018:8343052
pubmed: 30539022
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2611-6
pubmed: 16477023
Interferon. 1986;7:125-43
pubmed: 3102389
Mol Plant. 2010 Jan;3(1):2-20
pubmed: 20035037
Curr Drug Metab. 2002 Apr;3(2):175-87
pubmed: 12003349
Curr Pharm Des. 2007;13(33):3400-16
pubmed: 18045194
Int J Cancer. 2007 Nov 15;121(10):2225-32
pubmed: 17471564
Mini Rev Med Chem. 2011 Apr;11(4):298-344
pubmed: 21428901
J Agric Food Chem. 2007 Oct 31;55(22):8896-907
pubmed: 17902627
Biol Pharm Bull. 2003 Aug;26(8):1120-4
pubmed: 12913262

Auteurs

Stefanie Hofer (S)

Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria.
Institute of Pharmacy/Pharmacognosy, University of Innsbruck, Innrain 80-82/IV, 6020 Innsbruck, Austria.

Simon Geisler (S)

Institute of Biological Chemistry, Biocenter, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria.

Rebecca Lisandrelli (R)

Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria.

Hieu Nguyen Ngoc (H)

Institute of Pharmacy/Pharmacognosy, University of Innsbruck, Innrain 80-82/IV, 6020 Innsbruck, Austria.

Markus Ganzera (M)

Institute of Pharmacy/Pharmacognosy, University of Innsbruck, Innrain 80-82/IV, 6020 Innsbruck, Austria.

Harald Schennach (H)

Central Institute of Blood Transfusion and Immunology, University Hospital, Anichstrasse 35, 6020 Innsbruck, Austria.

Dietmar Fuchs (D)

Institute of Biological Chemistry, Biocenter, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria.

Julian E Fuchs (JE)

Department of Medicinal Chemistry, Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5- 11, 1120 Vienna, Austria.

Johanna M Gostner (JM)

Institute of Medical Biochemistry, Biocenter, Medical University of Innsbruck, Innrain 80, 6020 Innsbruck, Austria.

Katharina Kurz (K)

Department of Internal Medicine II, Infectious Diseases, Pneumology, Rheumatology, Medical University of Innsbruck, Anichstrasse 35, 6020 Innsbruck, Austria.

Classifications MeSH